News and Trends 8 Sep 2025 With Lykos CRL now public, FDA opens new era of accountability As the release of a CRL declining Lykos’ therapy generates a strong reaction from MAPS, delve into what this new transparency could change. September 8, 2025 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Podcast 15 Aug 2025Are next-generation psychedelics the way forward for addressing treatment resistant depression? This week’s guest is Cosmo Feilding of Beckley PsyTech, a UK biotech working with next generation psychedelics that could redefine depression treatment. August 15, 2025 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
Best in Biotech 12 Aug 2025 Six psychedelic drug companies aiming to revolutionize mental health treatment Discover six of the top psychedelic companies developing novel drugs to expand the treatment scope for mental health indications. August 12, 2025 - 2 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 27 Jun 2025 Psychedelics sans side effects: neuroplastogens gain ground The past year has seen several developments in the neuroplastogens field, including Elkedonia’s seed funding to address neuropsychiatric disorders. June 27, 2025 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 21 Mar 2025 Depression drug trials are failing—and placebos are to blame In this article, we examine recent clinical trial failures and discuss potential pathways forward for antidepressant drug research. March 21, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 12 Sep 2024New treatments being developed for schizophrenia Explore the latest strides in schizophrenia treatment development as 2024 heralds a pivotal year, with promising collaborations and trials. September 12, 2024 Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2024 Psychedelic therapies under scrutiny: What’s next after Lykos’ MDMA rejection? Delve into the psychedelic-assisted therapy market and investors’ sentiment after the FDA’s decision about Lykos’ therapy. September 6, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 25 Jan 2024 Eight mental health biotech companies trying to make a difference to people’s lives Take a closer look at eight mental health companies developing therapies that could make a different to people with mental illnesses. January 25, 2024 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2023 U.S. approval for psychedelic drug MDMA nears after success in clinic The psychedelic drug MDMA edges closer towards FDA approval for the treatment of post-traumatic stress disorder (PTSD) in the U.S., after promising results of a trial were published. This comes after Australia became the first country to allow doctors to prescribe the drug to those struggling with mental health disorders like PTSD and depression. Recognizing […] September 22, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2022 Beckley Psytech acquires Eleusis Therapeutics Beckley Psytech Limited has entered into a definitive agreement to acquire clinical-stage life science company Eleusis Therapeutics Limited in an all equity transaction. Under the terms of the agreement, which has been approved by shareholders, Beckley Psytech has acquired 100% of Eleusis, receiving full developmental and commercial rights for the company’s assets, which will further […] October 24, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2022 Spinoff Biohaven launches with $258M and “incredible pipeline” Biohaven Ltd. launched today as a new publicly traded company focused on delivering innovative life-changing treatments for neurological and neuropsychiatric diseases, including rare disorders. As of today, Biohaven has officially begun operating as a separate independent entity as part of the acquisition agreement with Pfizer in May 2022. The company, led by Vlad Coric as […] October 4, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2022 Drug for acute treatment of social anxiety disorder did not meet primary endpoint A nasal spray to treat anxiety did not meet its primary endpoint and was not significantly better than the placebo given during a phase 3 clinical trial. Vistagen Therapeutics Inc’s drug, PH94B, was designed to treat people living with anxiety, depression and other central nervous system (CNS) disorders announced the topline results on Friday (July […] July 25, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email